The ₹214.5 crore Q-Line Biotech IPO allotment is set to be finalized today, Tuesday, May 26, 2026, marking the end of the subscription period that ran from May 21-25, 2026. The grey market premium has strengthened to ₹115, according to Investorgain, signaling robust investor confidence ahead of the listing. The grey market premium peaked at ₹110 on May 20 before stabilizing in the current range, indicating sustained institutional backing. The grey market premium of ₹115 provides an unofficial indicator of market sentiment, with the premium reflecting strong institutional backing and structural growth in India's IVD diagnostics market post-COVID. As per The Economic Times, grey market trends indicate robust investor demand with shares commanding a grey market premium of around 36% ahead of listing on the NSE SME platform.
The ₹214.5 crore Q-Line Biotech IPO has been subscribed 95.31 times on Monday, May 25, demonstrating exceptional investor interest in the biotech company's shares. The healthcare solutions provider received bids for 42.62 crore equity shares against the offer size of 44.72 lakh shares via 2.35 lakh applications, with demand coming from across all investor categories. Non-institutional investors led the subscription at 146.3 times, followed by qualified institutional buyers at 123.9 times, while retail investors subscribed 71.4 times their allocated portion. The strong subscription follows the initial 102.42 times subscription during the three-day subscription period, with the final day showing particularly robust demand across all categories. As per The Economic Times, the IPO also raised around ₹61 crore from anchor investors ahead of opening for public subscription, further strengthening institutional backing.
The ₹214.5 crore initial share sale was exclusively a fresh issuance of 62.53 lakh equity shares, with no offer for sale (OFS) component. The IPO was priced in a price band of ₹326 to ₹343 per share, with the final issue price fixed at the upper end of the band at ₹343 per share. The least investment for an individual investor was two lots or 800 shares. The money raised will be utilized for ₹93.5 crore for working capital requirements, ₹90 crore for repayment of borrowings, and the remaining funds for general corporate purposes. As per The Economic Times, the company had fixed the price band at ₹326-343 per share and finalised the issue price at the upper end of the band at ₹343 apiece. The total issue size was ₹214.5 crores with the subscription period running from May 21-25, 2026, and shares credited to demat accounts on May 27, 2026.
According to reports from Chittorgarh, Q-Line Biotech develops, manufactures and markets reagents (including kits and POC devices) and consumables for diagnostic healthcare needs. The company's key manufacturing segments include indigenous manufacturing of reagents, including haematology, clinical chemistry, immunodiagnostics, molecular diagnostics and others (POC devices & rapid tests). Additionally, the company supplies and manufactures in vitro diagnostics (IVD), pathology equipment & devices. As per The Economic Times, incorporated in 2010, Q-Line Biotech operates in the diagnostics and healthcare products segment and is engaged in developing, manufacturing and marketing diagnostic reagents, kits, point-of-care devices and consumables used across healthcare and pathology services. The company also manufactures, imports and distributes diagnostic equipment catering to hospitals, medical colleges and diagnostic laboratories. As of December 2025, the company had annual manufacturing capacity of around 1.4 million diagnostic kits and 1,200 Selectra machines. The company established its first manufacturing plant at Bawana, New Delhi in 2016-17 and incorporated POCT Science House Private Limited in 2019 for running diagnostic laboratories. The company has over 15 years of experience in the diagnostics industry and serves 150-plus national and international clients.
As reported by Chittorgarh, shares of Q-Line Biotech will be listed on the NSE SME platform Emerge on Friday, May 29, 2026, at 10 am. Based on the final issue price of ₹343 per share, the grey market premium of ₹115 implies a likely listing price of around ₹466 in the unofficial market, as per The Economic Times. The expected listing price of ₹466 represents a 33.53% premium over the upper price band of ₹343, indicating strong market sentiment. The positive grey market sentiment comes amid continued investor appetite for healthcare and diagnostics-related businesses despite broader market volatility in SME stocks. Investors can track listing gains or losses through Kotak Neo and continue investing in the stock directly after the listing date. The allotment status can be checked on NSE and Purva Sharegistry (India) Pvt. Ltd - the registrar of the issue - using the step-by-step guide provided for both platforms. Hem Securities was the book-running lead manager to the issue, while Purva Sharegistry acted as the registrar and Hem Finlease was the market maker for the issue.
